Pharmacokinetic-pharmacodynamic modelling: History and perspectives

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 3, 2006, Pages 227-279

  Csajka, Chantal ^a   Verotta, Davide ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

History; Modelling; Pharmacodynamics; Pharmacokinetics; Review

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; COCAINE; CORTICOSTEROID; CYTARABINE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROCORTISONE; ITURELIX; LUTEINIZING HORMONE; METHYLPREDNISOLONE; NICOTINE; PREDNISOLONE; PROTHROMBIN COMPLEX; STEROID; TESTOSTERONE; VINBLASTINE; WARFARIN;

BASOPHIL; CARDIOVASCULAR SYSTEM; CELL ACTIVITY; CELL SURVIVAL; CIRCADIAN RHYTHM; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CYTOTOXIC T LYMPHOCYTE; DIURESIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TOLERANCE; EVOLUTION; FEEDBACK SYSTEM; HEART RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHERMIA; MATHEMATICAL MODEL; MEAL; MODULATION; NONHUMAN; NONLINEAR SYSTEM; PHARMACODYNAMICS; POPULATION MODEL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; URINARY EXCRETION; VASOCONSTRICTION; VASODILATATION; VIRUS PATHOGENESIS;

ALGORITHMS; COMPUTING METHODOLOGIES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY;

EID: 33745792813     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-9002-0     Document Type: Review

References (114)

1. D. Mager, E. Wyska, and W. Jusko. Diversity of mechanism-based pharmacodynamic models. Am. Soc. Pharmacol. Exp. Therapeut. 31:510-519 (2003).
2. R. J. Tallarida. Receptor theories and quantitative effect versus dose-concentration relationship. Drug Metab. Rev. 15:345-363 (1984).
3. D. Verotta and L. B. Sheiner. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J. Pharmacokin. Biopharm. 23:1-4 (1995).
4. N. Dayneka, V. Garg, and W. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478 (1993).
5. G. Levy. Mechanism-based pharmacodynamic modeling. Clin. Pharmacol. Therapeut. 56:356-358 (1994).
6. D. Verotta. Concepts, properties, and applications of linear systems to describe the distribution, identify input, and control endogenous substances and drugs in biological systems. CRC Crit. Rev. Biomol. Eng. 24:73-139 (1996).
7. D. Verotta. Semi-parametric direct and indirect action models for pharmacokinetics/pharmacodynamic data. In: Proceedings Society Computer Simulation Western Multiconference, Las Vegas, Nevada, USA, 1995.
8. G. Segre. Kinetics of interaction between drugs and biological system. Il Farmaco Ed. Sci. 23:907-918 (1968).
9. G. Levy. Kinetics of pharmacologic effects. Clin Pharm Therapeut. 7:362-372 (1966).
10. G. Levy. Relationship between elimination rate of drugs and rate of decline of their pharmacological effect. J. Pharm. Sci. 53:343-343 (1964).
11. G. Levy and E. Nelson. Theoretical relationship between dose, elimination rate, and duration of pharmacologic effect of drugs. J. Pharm. Sci. 54:812 (1965).
12. G. Levy. Apparent potentiating effect of a second dose of drug. Nature 206:517-519 (1965).
13. J. Wagner. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J. Theoret. Biol. 20:173-201 (1968).
14. E. Ariens. The mode of action of biologically active compounds. In: G De Stevens (ed.), Molecular Pharmacology. Academic Press, New York, 1964.
15. J. W. Black and P. Leff. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B. 220:141-162 (1983).
16. B. Tuk, M. Van Oostenbruggen, and V. M. M. Herben et al. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and ∝-OH-midazolam. J. Pharmacol. Exp. Therapeut. 289:1067-1074 (1999).
17. 1 receptors. J. Pharmacol. Exp. Therapeut. 283:809-816 (1997).
18. R. Furchgott. The pharmacology of vascular smooth muscle. Pharm. Res. 7:183-265 (1955).
19. J. Ferguson. The use of chemical potentials as indices of toxicity. Proc. Roy. Soc. London, s.B. 127:387-404 (1939).
20. M. Berman and M. F. Weiss. SAAM manual. U.S. Department of Health, Education and Welfare, Public Health Service Publication No. 1703. Washington, DC, U.S. Government Printing Office, 200 pp. 1967.
21. C. Boston, P. C. Greif, and M. Berman. Conversational SAAM - An interactive program for kinetic analysis of biological systems. Comput. Programs Biomed. 1981: 111-119 (1981).
22. SAAM. In Series. Seattle, WA: SAAM Institute, Inc. http://www.saam.com/ software/saam2/saam2software.htm.
23. B. Dahlstrom, L. Paalzow, and G. Segre et al. Relation between morphine pharmacokinetics and Analgesia. J. Pharmacokinet. Biopharm. 6:41-53 (1978).
24. G. Levy, M. Gibaldi, and W. Jusko. Multicompartment pkarmacokinetic models and pharmacologic effects. J. Pharm. Sci. 58:422-424 (1969).
25. R. Galeazzi, L. Benet, and L. Sheiner. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin. Pharmacol. Ther. 20:278-289 (1976).
26. W. Kramer, A. Kolibash, and R. Lewis et al. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7:47-61 (1979).
27. J. Mandema, P. Veng-Pedersen, and M. Danhof. Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. J. Pharmacokinet. Biopharm. 19:617-634 (1991).
28. L. Sheiner, D. Stanski, and S. Vozeh et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371 (1979).
29. W. Jusko. Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-non-specific agents. J. Pharm. Sci. 60:892-895 (1971).
30. W. Jusko. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J. Pharmacokinet. Biopharm. 1:175-200 (1973).
31. R. Nagashima, R. O'Reilly, and G. Levy. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10:22-35 (1969).
32. L. Sheiner. Computer-aided long-term anticoagulation therapy. Comput. Biomed. Res. 2:507-518 (1969).
33. T. Theophanus and R. Barile. Multiple-dose kinetics of oral anticoagulants: Methods of analysis and optimised dosing. J. Pharm. Sci. 62:261-266 (1973).
34. P. Abbrecht, T. O'Leary, and D. Behrendt. Evaluation of a computer-assisted method for individualized anticoagulation: Retrospective an prospective studies with a pharmacodynamic model. Clin. Pharmacol. Ther. 32: 129-136 (1982).
35. T. O'Leary, P. Abbrecht. Predicting oral anticoagulant response using a pharmacodynamic model. Ann. Biomed. Eng. 9: 199-216 (1981).
36. A. Sharma. Precursor-dependant indirect pharmacodynamic response model for tolerance and rebound phenomena. J. Pharm. Sci. 87:1577-1584 (1998).
37. J. Earp, W. Krzyzanski, and A. Chakraborty et al. Assessment of drug interactions relevant to pharmacodynamic indirect response models. J. Pharmacokine. Pharmacodynam. 31:345-380 (2004).
38. J. Wald. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J. Pharmacokinet. Biopharm. 19:521-536 (1991).
39. A. Kong, E. Ludwig, and R. Slaughter et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin. Pharmacol. Therpeut. 46:616-628 (1989).
40. T. Dunn, E. Ludwig, and R. Slaughter et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obese and on-obese men. Clin. Pharmacol. Therpeut. 50:536-549 (1991).
41. B. Frey, C. Walker, and F. Frey et al. Pharmacokinetics of three different prednisolone produrgs: effect on circulating lymphocyte subsets and function. J. Immunol. 133: 2479-2487 (1984).
42. A. Munck and K. Leung. Glucocorticoid receptors and mechanisms of action of steroid hormones. Receptors and Mechanisms of Action of Steroid Hormones. Marcel Dekker, New York, 1977, pp. 311-397.
43. R. Evans. The steroid and thyroid hormone receptor superfamily. Science 240: 889-895 (1988).
44. F. Boudinot, R. D'Ambrosio, and W. Jusko. Receptor-mediated pharmacodynamics of prednisolone in the rat. J. Pharmacokinet. Biopharm. 14: 469-493 (1986).
45. A. Nichols. Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokinet. Biopharm. 17:209-227 (1989).
46. Y. Sun and W. Jusko. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 87:732-737 (1998).
47. B. Oosterhuis, M. Braat, and C. Roos et al. Pharmacokinetic- pharmacodynamic modeling of terbutaline bronchodilation in asthma. Clin. Pharmacol. Therpeut 40:469-475 (1986).
48. D. Mager and W. Jusko. Pharmacodynamic modeling of time-dependent transduction systems. Clin. Pharmacol. Therpeut. 70:210-216 (2001).
49. E. Lobo and J. Balthasar. Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS Pharmaceut. Sci. 4:1-11 (2002).
50. R. Zahler, P. Wachter, and P. Jatlow et al. Kinetics of drug effect by distributed lags analysis: An application to cocaine. Clin. Pharmacol. Therpeut. 31:775-782 (1982).
51. E. Ekbad and V. Licko. A model eliciting transient responses. Am. J. Physiol. 246:R114-R121 (1984).
52. M. Chow, J. Ambre, and T. Ruo et al. Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Therpeutic. 38:318-324 (1985).
53. M. Hammarlund, B. Odling, and L. Paalzow. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-Pharmacodynamic modelling. J. Pharmacol. Exp. Therpeut. 233:447-453 (1985).
54. H. Porchet, N. Benowitz, and L. Sheiner. Pharmacodynamic model of tolerance: Application to nicotine. J. Pharmacol. Exp. Therpeut. 244:231 (1988).
55. J. Shi, N. Benowitz, and C. Denaro et al. Pharmacokinetic-pharmacodynamic modeling of caffeine: Tolerance to pressor effects. Clin. Pharmacol. Therpeut. 53:6-14 (1993).
56. J. W. Mandema and D. Wada. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J. Pharmacol. Exp. Therpeut. 279:1035-1042 (1995).
57. S. L. Shafer, L. C. Siegel, and J. E. Cooke et al. Testing computer-controlled infusion pumps by simulation. Anesthesiology 68:261-266 (1988).
58. S. L. Shafer and K. M. Gregg. Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer controlled infusion pump. J. Pharmacokinet Biopharm. 20:147-169 (1992).
59. D. Verotta. A general solution for non-parametric control of a linear system using computer controlled infusion pumps. IEEE Trans. Biomed. Eng. 46:44-50 (1999).
60. J. Bauer, J. Balthasar, and H. Fung. Application of pharmacodynamic modeling for designing time variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharm. Res. 14:114-145 (1997).
61. P. Francheteau, J. Steimer, and C. Dubray et al. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN203-922. J. Pharmacokinet. Biopharm. 19:287-309 (1991).
62. K. Lew, E. Ludwig, and M. Milad et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynmamics. Clin. Pharmacol. Therpeut. 54: 402-414 (1993).
63. J. Gries, N. Benowitz, and D. Verotta. Chronopharmacokinetics of nicotine. Clin. Pharmacol. Therpeut. 60:385-395 (1996).
64. C. Hull, H. Van Beem, and K. McLeod et al. A pharmacodynamic model for pancuronium. Brit. J. Anaesth. 50:1113-1123 (1978).
65. E. Fuseau and L. Sheiner. Simultaneous modeling of pharmacokinetic and pharmacodynamics with a nonparametric model. Clin. Pharmacol. Therpeut. 35:733-741 (1984).
66. J. Unadkat, F. Bartha, and L. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric and dynamic models. Clin. Pharmacol. Therpeut. 40:86-93 (1986).
67. D. Verotta and L. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics: An improved algorithm. Comput. Appl. Biostat. 3:345-349 (1987).
68. D. Verotta, S. Beal, and L. Sheiner. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am. J. Physiol. 256:R1005-R1010 (1989).
69. D. Verotta. An inequality-constrained least-squares deconvolution method. J. Pharmacokinet. Biopharm. 17:269-289 (1989).
70. P. Veng-Pedersen, J. Mandema, and M. Danhof. A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. J. Pharm. Sci. 80:488-495 (1991).
71. B. Tuk, M. Danhof, and J. Mandema. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J. Pharmacokinet. Biopharm. 25:39-60 (1997).
72. B. Tuk, V. Herben, and J. Mandema et al. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J. Pharmacol. Exp. Therpeut. 284:202-207 (1998).
73. D. Verotta and L. B. Sheiner. Semiparametric analysis of non-steady-state pharmacodynamic data. J. Pharmacokin. Biopharm. 19:691-712 (1991).
74. I. F. Troconiz, L. B. Sheiner, and D. Verotta. Semiparametric models for drug interactions. J. Appl. Physiol. 76:2224-2233 (1994).
75. N. Holford. Concepts and usefulness of pharmacokinetic-pharmacodynamic modeling. Fundament. Clin. Pharmacol. Therapeut. 4:93-101 (1990).
76. M. Rowland. Variability in Drug Therapy-Description, Estimation and Control. Raven Press Boks Ltd. New York (1985).
77. L. Sheiner, B. Rosenberg, and K. Melmon. Modeling of individual pharmacokinetics for computer-aided drug dosage. Comput. Biomed Res. 5:441-459 (1972).
78. S. Beal and L. B. Sheiner. NONMEM I Users Guide. Technical Report, Division of Clinical Pharmacology, University of California at San Francisco, 1984.
79. L. Yuh, S. Beal, and M. Davidian et al. Population pharmacokinetic/ pharmacodynamic methodology and applications: A bibliography. Biometrics. 50:566-575 (1994).
80. L. Sheiner and T. Ludden. Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 32:185-209 (1992).
81. L. Sheiner and S. Beal. Bayesian individualisation of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 71:1344-1348 (1982).
82. C. Minto. Expanding clinical applications of population pharmacodynamic modeling. Brit. J. Clin. Pharmaco. 46:321-333 (1998).
83. A. J. Boeckmann, S. L. Beal, and L. B. Sheiner. NONMEM V Users Guides. Technical Report, Division of Clinical Pharmacology, University of California at San Francisco, 1998.
84. WinNonmix®. Pharsight. http://www.pharsight.com/products/winnonmix/ index.php.
85. D. D'Argenio and A. Schumitzky. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. In Series ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles, 1997.
86. PopKinetics. SI, INC. http://www.saam.com/software/popKinetics/ popKineticsSoftware.htm.
87. PKBUGS. MRC Biostatistics Unit, Cambridge, UK. http://www.mrc-bsu.cam.ac. uk/bugs/winbugs/pkbugs.shtml.
88. K. Fattinger, D. Verotta, and H. Porchet et al. Modelling a bivariate control system: LH and testosterone response to the GnRH antagonist Antide. Am. J. Physiol. 271: E775-E787 (1996).
89. K. Zuideveld, H. Maas, and N. Treijtel et al. A set-point model with oscillatory behaviour predicts the time course of (8-)-OH-DPAT induced hypothermia. Am. J. Physiol. 281: R2059-R2071 (2001).
90. N. A. Bridges, P. C. Hindsmarsh, and P. J. Pringle et al. The relationship between endogenous testosterone and gonadotropin secretion. Clin. Endocrinol. 38:373-378 (1993).
91. S. Bonhoeffer, R. M. May, and G. M. Shaw et al. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA. 94:6971-6976 (1997).
92. M. A. Nowak and R. M. May. Mathematical biology of HIV infections: Antigenetic variation and diversity threshold. Math. Biosci. 106:1-21 (1991).
93. M. A. Nowak, S. Bonhoeffer, and G. M. Shaw et al. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell population. J. Theoret. Biol. 184:203-217 (1997).
94. L. M. Wein, R. M. DAmato, and A. S. Perelson. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J. Theoret. Biol. 192: 81-98 (1998).
95. M. A. Stafford, L. Corey, and Y. Cao et al. Modelling plasma virus concentration during primary HIV infection. J. Theoret. Biol. 203: 285-301 (2000).
96. Y. Huang and L. Wu. Mechanistic PK/PD modeling of antiretroviral therapies in AIDS clinical trials. In Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Vol. III. Kluwer Academic Publishers, Boston, 2004, pp. 221-238.
97. M. A. Nowak and R. M. May. Coexistence and competition in HIV infections. J. Theoret. Biol. 159:329-342 (1992).
98. A. S. Perelson and P. Essunger. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387:188-191 (1997).
99. A. S. Perelson, A. U. Neumann, and M. Markowitz et al. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1587 (1996).
100. H. Wu and A. A. Ding. Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55:410-418 (1999).
101. A. A. Ding and H. Wu. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics 56:293-300 (2000).
102. D. Verotta and F. Schaedeli. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. Math. Biosci. 176: 163-183 (2002).
103. R. M. May. Nonlinearity and complex behavior in simple ecological and epidemiological models. Perspect. Biol. Dynam. Theoret. Med. 504:1-15 (1987).
104. D. Verotta. Models and estimation methods for clinical HIV-1 data. J. Comput. Appl. Math., in press.
105. B. Efron and D. Feldman. Compliance as an explanatory variable in clinical trial. J. Am. Stat.Assoc. 86:9-17 (1991).
106. J. Urquhart and E. De Klerk. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat. Med. 17:251-267: discussion 387-259 (1998).
107. Homer. Iliad, Book XIII; c. 850 BC.
108. C. M. Metzler. A user's manual for NONLIN. The Upjohn Co. Techn. Rep. 7292/69/7292/005. Kalama 700. Mich., 1969.
109. A. Gelman, J. B. Carlin, and H. Stern et al. Bayesian Data Analysis. Chapman & Hall, London, 1995.
110. J. J. Distefano-III and E. M. Landaw. Multiexponential, multicompartmental, and noncompartmental modeling. I. Methodological limitations and physiological interpretations. Am. J. Physiol. Regulat. Integrat. Comp. Physiol. 15:(1984).
111. D. Verotta. Volterra series in pharmacokinetics and pharmacodynamic. J. Pharmacokinet. Pharmacodynam. 30:337-362 (2003).
112. V. Volterra. Theory of Functionals and of integral and Integro-Differential Equations. Dover, New York, 1959.
113. V. Z. Marmarelis. Identification of nonlinear biological systems using laguerre expansions of kernels. Ann. Biomed. Eng. 21:573-589 (1993).
114. C. DeBoor. A Practical Guide to Splines, 1978.